194 related articles for article (PubMed ID: 35525883)
1. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.
Vallejo M; Muñiz P; Kwon M; Solán L; Bailén R; Carbonell D; Chicano M; Suárez-González J; Catalán P; Bellón JM; Triviño JC; Dorado N; Gallardo D; Díez-Martín JL; Ramírez N; Martínez-Laperche C; Buño I
Ann Hematol; 2022 Jul; 101(7):1567-1576. PubMed ID: 35525883
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
[TBL] [Abstract][Full Text] [Related]
5. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
Eberhardt KA; Jung V; Knops E; Heger E; Wirtz M; Steger G; Kaiser R; Affeldt P; Holtick U; Klein F; Scheid C; Di Cristanziano V
Bone Marrow Transplant; 2023 Jun; 58(6):639-646. PubMed ID: 36869190
[TBL] [Abstract][Full Text] [Related]
6. An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Pascual MJ; Gago B; Piñana JL; Hernández-Boluda JC; Vázquez L; García M; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Med Microbiol Immunol; 2020 Feb; 209(1):15-21. PubMed ID: 31478067
[TBL] [Abstract][Full Text] [Related]
7. The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.
Wu X; Ma X; Song T; Liu J; Sun Y; Wu D
Ann Hematol; 2024 Mar; 103(3):917-933. PubMed ID: 38227006
[TBL] [Abstract][Full Text] [Related]
8. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation.
Takenaka K; Onishi Y; Mori T; Hirakawa T; Tada Y; Uchida N; Kobayashi T; Kanda Y; Ozawa Y; Ota S; Iida H; Fukushima K; Kimua T; Fukuda T; Atsuta Y; Matsuto K; Yamazaki H; Nakasone H
Transplant Cell Ther; 2021 Jan; 27(1):82.e1-82.e8. PubMed ID: 33039517
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea.
Kang KW; Jeon MJ; Yu ES; Kim DS; Lee BH; Lee SR; Choi CW; Park Y; Kim BS; Sung HJ
PLoS One; 2023; 18(9):e0291268. PubMed ID: 37703263
[TBL] [Abstract][Full Text] [Related]
10. Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients.
Cui J; Zhou Y; Zhao K; Li X; Zhang H; Zhang X; Sun Y; Long B
Clin Transplant; 2024 Apr; 38(4):e15300. PubMed ID: 38555576
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
12. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation.
Kawamura S; Nakasone H; Takeshita J; Kimura SI; Nakamura Y; Kawamura M; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Akahoshi Y; Kusuda M; Kameda K; Tanihara A; Tamaki M; Kako S; Kanda Y
Transplant Cell Ther; 2021 Aug; 27(8):683.e1-683.e7. PubMed ID: 33984537
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation.
Casto AM; Seo S; Levine DM; Storer BE; Dong X; Hansen JA; Boeckh M; Martin PJ
Blood; 2021 Oct; 138(17):1628-1636. PubMed ID: 34269803
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification.
Dziedzic M; Sadowska-Krawczenko I; Styczynski J
Anticancer Res; 2017 Dec; 37(12):6551-6556. PubMed ID: 29187429
[TBL] [Abstract][Full Text] [Related]
17. PTX3 Polymorphisms Influence Cytomegalovirus Reactivation After Stem-Cell Transplantation.
Campos CF; Leite L; Pereira P; Vaz CP; Branca R; Campilho F; Freitas F; Ligeiro D; Marques A; Torrado E; Silvestre R; Lacerda JF; Campos A; Cunha C; Carvalho A
Front Immunol; 2019; 10():88. PubMed ID: 30766534
[No Abstract] [Full Text] [Related]
18. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and viral load patterns in children with cytomegalovirus gastrointestinal disease after allogeneic hematopoietic stem cell transplantation.
Kang HM; Kim SK; Ryu IH; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B
Bone Marrow Transplant; 2021 Nov; 56(11):2813-2819. PubMed ID: 34274956
[TBL] [Abstract][Full Text] [Related]
20. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
